Company announces positive results from Phase 3 Study cyclobenzaprine hydrochloride sublingual tablets for fibromyalgia

Phase 3 RELIEF study (n=503) met its pre-specified primary endpoint; cyclobenzaprine hydrochloride (a novel, non-opioid, centrally-acting analgesic) significantly reduced daily pain vs. placebo (p=0.01) at 14 weeks in participants with fibromyalgia.

Source:

Biospace Inc.